99mTcN核标记的新型心肌灌注显像剂的研究

通过配体交换反应制备了[99mTcN(PNP5)(DEDC)]+和[99mTcN(PNP5)(DPODC)]+两种新配合物, 其放化纯度均大于90%. 生物性能研究结果表明: 两种配合物在小鼠心肌中的初始摄取高, 肝、肺等非靶组织清除快, 靶/非靶比高, 有利于早期心肌显像. 其中, [99mTcN(PNP5)(DEDC)]+在小鼠中的性质较优, 且其在狗体内的性质接近99mTc-tetrofosmin, 有望成为一种新型心肌灌注显像剂.     

99mTc标记COI配合物的制备及其用作心室显像剂的初步研究

通过改变异腈配体的结构和配合物的中心核,以期获得标记方法简单、放化纯度高以及生物性能优良的新型心室显像剂.以环辛胺为原料,通过甲酰胺化和脱水两步反应制得配体环辛基异腈(COI),并以氯化亚锡为还原剂和二硫代肼基甲酸甲酯为供氮体,通过配体交换反应得到放化纯度大于95%的^99mTcN-COI标记物.以氯化亚锡为还原剂直接标记制得放化纯度大于95%的^99mTc-COI配合物.两种标记物在室温下放置6h以上,其放化纯度无明显变化.在正常昆明小鼠体内进行的生物分布实验研究结果显示,^99mTcN-COI和^99mTc-COI在心脑中有一定摄取,但肝、肺及血等本底摄取相对较高.二者在血液中都有很高的浓集,且滞留也很好,其中^99mTc-COI配合物在静脉注射后60min时的血/心、血/肝和血/肺摄取比分别为6.67,1.54和2.07,有望成为一种新型的制备方法简单的心室显像剂.     

PET心肌灌注显像剂

由于PET在心肌灌注显像方面具有高分辨率、高灵敏度、低组织衰减和心肌血流定量等优势而使得PET心肌灌注显像剂的研究日益受到关注。本文介绍了目前已经应用于临床的PET心肌灌注显像剂的情况,分别综述了 ¹⁸F 标记和其他正电子核素标记的PET心肌灌注显像剂的研究进展,重点讨论了几种亲脂性阳离子类和线粒体复合物Ⅰ(MC-Ⅰ)抑制剂类 ¹⁸F 标记心肌灌注显像剂,特别是近年取得突破性进展的MC-Ⅰ抑制剂类心肌灌注显像剂(如BMS-747158-02和[¹⁸F]FP1OP),介绍了各类PET心肌灌注显像剂的生物性能、心肌摄取机制,对其优缺点进行比较,并对PET心肌灌注显像剂的应用前景进行了展望。     

一种新型脑灌注显像剂99mTcN-CPDTC的制备及生物分布

目前临床上广泛使用的99mTc脑灌注显像剂是以［99mTcO］3+核为中心核的配合物99mTc-乙撑双半胱氨酸二乙酯(99mTc-ECD)和99mTc-六甲基丙撑二胺肟(99mTc-HMPAO). ［99mTc≡N］2+核由于具有较高的化学稳定性以及用99mTcN核代替99mTcO核后其配合物的生物分布性能发生了较大的改变［1～3］, 因此研究含99mTcN核的配合物成为寻找新型放射性药物的一条有效途径.     

一种新的潜在心肌显像剂[99mTc(CO)3(TBI)3]+的制备及其生物分布研究

以[99mTcO4]-为起始物,在0.1MPa下制备了中间体[99mTc(CO)3(H2O)1]+,通过配体交换反应,叔丁基异腈(TBI)配体取代该配合物中的3个水分子,制得一种标记率大于90%的[99mTc(CO)1(TBI)1]+配合物.该配合物在室温下放置6h以上,标记率无明显变化.在正常昆明小鼠体内的生物分布实验结果表明,[99mTc(CO)3(TBI)3]+具有较高的心肌摄取,且滞留也相当好,在静脉注射5min和60min后时的心肌摄取值分别为(19.07±0.81)%(ID/g)和(18.24±2.41)%(ID/g).该配合物的非靶本底摄取较低,注射60min后的心/肝、心/肺和心/血摄取比值分别为1.02,5.83和23.69,有望发展为一种新的心肌显像剂.     

新的99mTc标记N2S+X型脑灌注显像剂的筛选

基于^99mTcO-MPBDA-Cl的优良实验结果, 合成了两种新的配体MPTDA和MPDAA, 并加入不同的卤离子形成一系列^99mTcO³⁺配合物, 进行了理化性质的测试和动物实验, 结果表明MPTDA和MPDAA形成的配合物脂溶性比MPBDA形成的配合物有所提高, 依然保持该类化合物良好的脑滞留性能；但血液中放射性摄取偏高, 导致脑血比值偏低. 氟、溴、碘阴离子的引入对于脑摄取和脑滞留有较大影响. 结合理论计算对实验结果进行了合理解释, 对N₂S+X型的脑灌注显像剂进行了筛选. 综合脑摄取、脑滞留和毒性等各种因素, 确认^99mTcO-MPBDA-Cl具有成为新型脑灌注显像剂的潜力.     

脑显像剂~（99m）Tc－ECD的制备研究

~（９９ｍ）Ｔｃ－ＥＣＤ是目前脑显像剂中一种较为理想的放射性诊断药物。本文介绍了从基本原料（Ｌ）半胱氨酸开始合成配体ＥＣＤ（Ｎ，Ｎ＇－乙撑－双－Ｌ半胱氨酸乙酯），采用锡作还原剂实现了一步法~（９９ｍ）Ｔｃ标记ＥＣＤ，并对制备的~（９９ｍ）Ｔｃ－ＥＣＤ进行了初步动物实验以评价其生物学性能。     

两种新型99mTcN核标记的甲硝唑类乏氧显像剂的制备及生物性能评价

为研制新的肿瘤乏氧显像剂, 设计合成了2-(2-甲基-5-硝基咪唑基)乙基氨荒酸钾(MNIE-DTC)和4-(2-甲基-5-硝基咪唑基)丁基氨荒酸钾(MNIB-DTC)两种氨荒酸盐配体, 并制得了相应的99mTcN核配合物99mTcN(MNIE-DTC)2和99mTcN(MNIB-DTC)2. 所获得的两种99mTcN核配合物均为电中性, 具有较高的体外稳定性. 在荷乳腺癌的TA-2小鼠体内分布实验结果显示, 两种配合物均具有一定的肿瘤摄取, 给药1 h后, 99mTcN(MNIE-DTC)2和99mTcN(MNIB-DTC)2的肿瘤摄取率分别为(0.50±0.01)%ID/g和(0.64±0.10)%ID/g. 注入肼苯哒嗪后, 两种配合物的肿瘤摄取明显增高, 表明这两种配合物都具有对乏氧肿瘤的选择性.     

一种新型Ni(Ⅱ)配位聚合物{[Ni(C18H18N4O5)(DMF)]·(DMF)}n的合成、晶体结构和性质研究

溶剂热法合成了1个新配位聚合物{[Ni(C₁₈H₁₈N₄O₅)(DMF)]·(DMF)}_n。通过元素分析、红外光谱、热重以及X-射线单晶洐射对其进行了表征。该晶体为正交晶系,Pna2₁空间群。该化合物中,C₁₈H₁₈N₄O₅配体通过5个配位原子以及相邻的溶剂分子DMF上的1个配位原子与Ni(Ⅱ)原子配位,形成了1个扭曲的八面体配位构型。热重分析表明该化合物在140 ℃开始发生分解。     

[99mTcN(PNP5)(NOEt)]+: A novel potential myocardial perfusion imaging agent

Summary The asymmetrical [^99mTcN(PNP5)(NOEt)]⁺heterocomplex containing a terminal technetium-nitrogen multiple bond coordinated to the diphosphine ligand (PNP5) and the dithiocarbamate ligand (NOEt), was prepared through ligand exchange reaction. Its radiochemical purity was over 90% as measured by TLC and HPLC. Biodistribution in mice and SPECT imaging in dog were studied. The results showed that [^99mTcN(PNP5)(NOEt)]⁺ possessed high myocardial uptake and good retention, and high target to non-target ratios, suggesting that it may be a potential myocardial perfusion imaging agent.     

Radiosynthesis and evaluation of novel [99mTc(I)]+ and [99mTc(I)(CO)3]+ complexes with a 4-nitroimidazole isocyanide for imaging tumor hypoxia

[^99mTc(I)]⁺ and [^99mTc(I)(CO)₃]⁺ complexes with isocyanide exhibit high stability, which makes them suitable platforms to develop novel ^99mTc radiopharmaceuticals. To develop novel ^99mTc radiotracers for imaging hypoxia, in this study, a novel L ligand (4-nitroimidazole isocyanide derivative) was synthesized and labelled using [^99mTc(I)]⁺ core and [^99mTc(I)(CO)₃]⁺ core to produce [^99mTc(L)₆]⁺ and [^99mTc(CO)₃(L)₃]⁺ with high yields. To verify the structure of the ^99mTc complexes, corresponding rhenium analogues were synthesized and characterized. Both of the ^99mTc complexes were stable and hydrophilic. in vitro cellular uptake results showed they could exhibit good hypoxic selectivity. The evaluation of biodistribution in mice bearing S180 tumors indicated both of them could accumulate in tumor. Between them, [^99mTc(L)₆]⁺ exhibited higher tumor uptake and tumor/non-target ratio than [^99mTc(CO)₃(L)₃]⁺. Further, single photon emission computed tomography (SPECT) imaging studies of [^99mTc(L)₆]⁺ indicated an obvious accumulation in tumor and the value of the region-of-interest (ROI) ratio of the uptake for the tumor site to the corresponding non-tumor region was 5.64 ± 0.52. The above results suggested [^99mTc(L)₆]⁺ would be a potential tracer for imaging tumor hypoxia.     

Design,Preparation, and Evaluation of a Novel 99mTcN Complex of Ciprofloxacin Xanthate as a Potential Bacterial Infection Imaging Agent

In order to seek novel technetium-99m bacterial infection imaging agents, a ciprofloxacin xanthate (CPF2XT) was synthesized and radiolabeled with [^99mTcN]²⁺ core to obtain the ^99mTcN-CPF2XT complex, which exhibited high radiochemical purity, hydrophilicity, and good stability in vitro. The bacteria binding assay indicated that ^99mTcN-CPF2XT had specificity to bacteria. A study of biodistribution in mice showed that ^99mTcN-CPF2XT had a higher uptake in bacterial infection tissues than in turpentine-induced abscesses, indicating that it could distinguish bacterial infection from sterile inflammation. Compared to ^99mTcN-CPFXDTC, the abscess/blood and abscess/muscle ratios of ^99mTcN-CPF2XT were higher and the uptakes of ^99mTcN-CPF2XT in the liver and lung were obviously decreased. The results suggested that ^99mTcN-CPF2XT would be a potential bacterial infection imaging agent.     

Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities

The favorable nuclear properties in combination with the rich coordination chemistry make technetium-99m the radioisotope of choice for the development of myocardial perfusion tracers. In the early 1980s, [^99mTc]Tc-Sestamibi, [^99mTc]Tc-Tetrofosmin, and [^99mTc]Tc-Teboroxime were approved as commercial radiopharmaceuticals for myocardial perfusion imaging in nuclear cardiology. Despite its peculiar properties, the clinical use of [^99mTc]Tc-Teboroxime was quickly abandoned due to its rapid myocardial washout. Despite their widespread clinical applications, both [^99mTc]Tc-Sestamibi and [^99mTc]Tc-Tetrofosmin do not meet the requirements of an ideal perfusion imaging agent due to their relatively low first-pass extraction fraction and high liver absorption. An ideal radiotracer for myocardial perfusion imaging should have a high myocardial uptake; a high and stable target-to-background ratio with low uptake in the lungs, liver, stomach during the image acquisition period; a high first-pass myocardial extraction fraction and very rapid blood clearance; and a linear relationship between radiotracer myocardial uptake and coronary blood flow. Although it is difficult to reconcile all these properties in a single tracer, scientific research in the field has always channeled its efforts in the development of molecules that are able to meet the characteristics of ideality as much as possible. This short review summarizes the developments in ^99mTc myocardial perfusion tracers, which are able to fulfill hitherto unmet medical needs and serve a large population of patients with heart disease, and underlines their strengths and weaknesses, the lost and found opportunities thanks to the developments of the new ultrafast SPECT technologies.     

Preparation and Evaluation of Novel Folate Isonitrile 99mTc Complexes as Potential Tumor Imaging Agents to Target Folate Receptors

In order to seek novel technetium-99m folate receptor-targeting agents, two folate derivatives (CN5FA and CNPFA) were synthesized and radiolabeled to obtain [^99mTc]Tc-CN5FA and [^99mTc]Tc-CNPFA complexes, which exhibited high radiochemical purity (>95%) without purification, hydrophilicity, and good stability in vitro. The KB cell competitive binding experiments indicated that [^99mTc]Tc-CN5FA and [^99mTc]Tc-CNPFA had specificity to folate receptor. Biodistribution studies in KB tumor-bearing mice illustrated that [^99mTc]Tc-CN5FA and [^99mTc]Tc-CNPFA had specific tumor uptake. Compared with [^99mTc]Tc-CN5FA, the tumor/muscle ratios of [^99mTc]Tc-CNPFA were higher, resulting in a better SPECT/CT imaging background. According to the results, the two ^99mTc complexes have potential as tumor imaging agents to target folate receptors.     

Excited-state dynamics of fac-[ReI(L)(CO)3(phen)]+ and fac-[ReI(L)(CO)3(5-NO2-phen)]+ (L = imidazole, 4-ethylpyridine; phen = 1,10-phenanthroline) complexes

The nature and dynamics of the lowest excited states of fac-[Re(I)(L)(CO)(3)(phen)](+) and fac-[Re(I)(L)(CO)(3)(5-NO(2)-phen)](+) [L = Cl(-), 4-ethyl-pyridine (4-Etpy), imidazole (imH); phen = 1,10-phenanthroline] have been investigated by picosecond visible and IR transient absorption spectroscopy in aqueous (L = imH), acetonitrile (L = 4-Etpy, imH), and MeOH (L = imH) solutions. The phen complexes have long-lived Re(I) --> phen (3)MLCT excited states, characterized by CO stretching frequencies that are upshifted relative to their ground-state values and by widely split IR bands due to the out-of-phase A'(2) and A"nu(CO) vibrations. The lowest excited states of the 5-NO(2)-phen complexes also have (3)MLCT character; the larger upward nu(CO) shifts accord with much more extensive charge transfer from the Re(I)(CO)(3) unit to 5-NO(2)-phen in these states. Transient visible absorption spectra indicate that the excited electron is delocalized over the 5-NO(2)-phen ligand, which acquires radical anionic character. Similarly, involvement of the -NO(2) group in the Franck-Condon MLCT transition is manifested by the presence of an enhanced nu(NO(2)) band in the preresonance Raman spectrum of [Re(I)(4-Etpy)(CO)(3)(5-NO(2)-phen)](+). The Re(I) --> 5-NO(2)-phen (3)MLCT excited states are very short-lived: 7.6, 170, and 43 ps for L = Cl(-), 4-Etpy, and imH, respectively, in CH(3)CN solutions. The (3)MLCT excited state of [Re(I)(imH)(CO)(3)(5-NO(2)-phen)](+) is even shorter-lived in MeOH (15 ps) and H(2)O (1.3 ps). In addition to (3)MLCT, excitation of [Re(I)(imH)(CO)(3)(5-NO(2)-phen)](+) populates a (3)LLCT (imH --> 5-NO(2)-phen) excited state. Most of the (3)LLCT population decays to the ground state (time constants of 19 (H(2)O), 50 (MeOH), and 72 ps (CH(3)CN)); in a small fraction, however, deprotonation of the imH.+ ligand occurs, producing a long-lived species, [Re(I)(im.)(CO)(3)(5-NO(2)-phen).-]+.